Latest Mdr News

MedAdvisor Limited has appointed John Ciccio as its new CEO and Managing Director, marking a strategic leadership shift aimed at capitalising on recent technology advancements and US market growth.

MedAdvisor Solutions reported a steep 52.8% revenue decline in Q1 FY26, impacted by US regulatory pressures and vaccine program delays, while embarking on a strategic transformation to restore growth.

MedAdvisor reports a sharp 53% drop in 1Q FY26 revenue driven by U.S. regulatory and sector challenges, while advancing a major platform transformation and selling its ANZ business to emerge debt-free.

MedAdvisor Limited will have its trading suspension lifted on 10 October 2025 following the lodgement of its annual financial report, marking a key moment for investors.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

MedAdvisor Limited reported a staggering $60.2 million loss for FY25, driven by operational challenges and asset impairments, while divesting its ANZ business and becoming debt-free.

MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.

MedAdvisor reports a significant revenue decline in FY25 amid US program delays but strengthens its balance sheet through a capital raise and ANZ business sale. The company signals a strategic pivot with potential US business divestment on the horizon.

MedAdvisor Limited has finalized the sale of its Australian and New Zealand operations to Jonas Software for an estimated $42.35 million, marking a strategic pivot towards its US business. The company also announced upcoming CFO changes as it refocuses its growth trajectory.

MedAdvisor Limited has entered a binding agreement to sell its ANZ business division and intellectual property to Jonas Software for a headline price of $35 million plus an uncapped earn-out. The deal marks a strategic pivot as MedAdvisor focuses on its US operations.

MedAdvisor Limited has successfully closed its Share Purchase Plan, raising $2.668 million—exceeding its $2 million target—and plans an upcoming shareholder meeting to approve director share issuances.

MedAdvisor Limited has entered a non-binding agreement to sell its ANZ business division for a headline price of $35 million plus a potential earn-out, marking a significant strategic shift.